|ZFIN ID: ZDB-IMAGE-180823-11|
CaPs expressed reduced levels of Isl1/2 immunoreactivity in islet2a mutant embryos.
(A) In 28 hpf tg(mnx1:gfp) wildtype (wt, n = 15) embryos, CaPs (*) expressed both gfp (green) and Isl1/2 immunoreactivity (red), as revealed by the merged yellow signal. (B) The Isl11/2 immunosignal of Panel A is shown separately. In A-D, dotted lines circle the cell bodies of CaP/VaPs that were immunopositive for Isl1/2. In comparison to other ventral neurons, CaP Isl1/2 immunolabeling was more intense. (C) In 28 hpf tg(mnx1:gfp) mutant (mut, n = 14) embryos, CaPs (*) expressed gfp. However, compared to wildtype (A), the CaP Isl1/2 fluorescent immunolabel signal was less intense. Further, other ventral neurons continued to display Isl1/2 immunoreactivity. (D) The Isl1/2 signal of Panel C is viewed separately. Compared to wildtype (B), CaPs expressed reduced levels of Isl1/2 immunoreactivity. Further, despite the weak signal in CaPs, Isl1/2 immunoreactivity was present in other ventral neurons at levels similar to wildtype (B). Scale bar in D for A-D: 25 μm. (E, F) Examination of CaP Isl1/2 immunolabeling dorsal to the proctodeum. (E) In wildtype embryos, both the proctodeum (white arrow) and CaPs (asterisks) displayed Isl1/2 immunolabeling. One CaP, contained within white dotted line box, is shown at higher magnification in the inset. (F) In mutant embryos, Isl1/2 immunolabeling was not detected in the proctodeum, consistent with loss of Islet2a protein expression. Despite this, a low level of Isl1/2 immunoreactivity persisted in CaPs (asterisks; one CaP shown at higher power in inset).
|Acknowledgments:||This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image.|